Teva Pharmaceutical Industries Limited vs Eli Lilly & Co.
TEVA vs LLY — side-by-side comparison from reported financials. TEVA leads 2, LLY leads 9 of 11 comparable metrics.
Teva Pharmaceutical Industries Limited
TEVA · Healthcare
$41.21+4.99%Strained
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | TEVA | LLY |
|---|---|---|
| Price | $41.21 | $1 177.20 |
| Market cap | $48.1B | $1.05T |
| Revenue (TTM) | $17.3B | $79.7B |
| Revenue growth | +5.0% | +31.7% |
| Net margin | 4.1% | 33.5% |
| Free cash flow | $1.35B | $18.2B |
| Net cash (debt) | $1.74B | ($35.2B) |
| 1-year price return | +105.6% | +37.6% |
| P/E | 63.2 | 41.6 |
| P/E vs own history (cheap-side %) | 0% | 88% |
| Dividend yield | — | 0.52% |
| Return on equity | 9% | 93% |
| Altman Z-score | 0.63 | 7.10 |
| CV checks passed | 7 of 10 | 11 of 10 |
| Employees | 32,842 | 50,000 |
Full résumé-style profiles: TEVA CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.